ŠIMARA, Pavel, Stanislav STEJSKAL, Martina PETERKOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL and Jiří MAYER. Determination of pCrkL level in chronic myeloid leukaemia cells using flow cytometry. In Advances in Molecular and Cancer Biology, 2010. Brno, Česká Republika: muni PRESS, 2010, p. 43-45. ISBN 978-80-210-5312-0.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Determination of pCrkL level in chronic myeloid leukaemia cells using flow cytometry
Authors ŠIMARA, Pavel (203 Czech Republic, belonging to the institution), Stanislav STEJSKAL (203 Czech Republic, belonging to the institution), Martina PETERKOVÁ (203 Czech Republic, belonging to the institution), Irena KRONTORÁD KOUTNÁ (203 Czech Republic, guarantor, belonging to the institution), Zdeněk RÁČIL (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution).
Edition Brno, Česká Republika, Advances in Molecular and Cancer Biology, 2010, p. 43-45, 3 pp. 2010.
Publisher muni PRESS
Other information
Original language English
Type of outcome Proceedings paper
Field of Study 10601 Cell biology
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Publication form printed version "print"
RIV identification code RIV/00216224:14330/10:00045382
Organization unit Faculty of Informatics
ISBN 978-80-210-5312-0
Keywords in English CML; imatinib; CD34+; pCrkL; flow cytometry
Tags Reviewed
Changed by Changed by: Mgr. Pavel Šimara, Ph.D., učo 67594. Changed: 2/3/2018 10:23.
Abstract
Imatinib is a tyrosine kinase inhibitor nowadays used as a first line therapy for newly diagnosed chronic myeloid leukaemia (CML) patients. However, some of the patients relapse after initially good response. Therefore, reliable methods for predicting of the imatinib treatment response are sought. In our research we determine the level of phosphorylated CrkL protein, known as a substrate of Bcr-Abl, by flow cytometry. Its potential predictive value as a marker of imatinib treatment response will be assessed in the monuclear cells or CD34+ cells of peripheral blood samples of new CML patients.
Links
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
2B06052, research and development projectName: Vytipování markerů, screening a časná diagnostika nádorových onemocnění pomocí vysoce automatizovaného zpracování multidimenzionálních biomedicínských obrazů (Acronym: Biomarker)
Investor: Ministry of Education, Youth and Sports of the CR, Determination of markers, screening and early diagnostics of cancer diseases using highly automated processing of multidimensional biomedical images
PrintDisplayed: 20/8/2024 03:27